Figure 1.
Consort diagram delineates treatment distribution of the entire cohort of 29 patients. Twenty-five patients received blinatumomab as the mAb1 and inotuzumab as the mAb2. Four patients received inotuzumab mAb1 and blinatumomab mAb2.
Consort diagram delineates treatment distribution of the entire cohort of 29 patients. Twenty-five patients received blinatumomab as the mAb1 and inotuzumab as the mAb2. Four patients received inotuzumab mAb1 and blinatumomab mAb2.